Granted Patent B2

US 12,326,451 · App. 16/936,752 · Granted Jun 10, 2025

Inventors: Sylvie Van Der Werf (Paris, FR); Nicolas Escriou (Paris, FR); Caroline Demeret (Paris, FR); Stéphane Petres (Paris, FR); Pierre Lafaye (Paris, FR); Jacques Bellalou (Paris, FR)

Assignee: INSTITUT PASTEUR

G01N33/56983C07K14/005C12N15/70C12N2770/20022C12N2770/20031G01N2333/165G01N2800/26

Abstract

Claims (23)

1. A kit for detection of a severe acute respiratory syndrome (SARS)-associated coronavirus infection in a biological sample comprising:

a severe acute respiratory syndrome-associated coronavirus 2 nucleocapsid protein (SARS-CoV-2 N protein) fused to a N-terminally located poly-histidine tag containing 6 histidines, made by a process comprising expressing and purifying said SARS-CoV-2 N protein fused to a N-terminally located poly-histidine tag containing 6 histidines from Escherichia coli ( E. coli ) strain BL21 (DE3) pDIA17 transformed with recombinant plasmid pETM11/N-nCov E. coli 3-(His) 6-Nter or pETM11/N-nCov E. coli 4-(His) 6-Nter deposited at the Collection Nationale de Cultures de Microorganismes (CNCM) at the Institut Pasteur, 25, Rue du Docteur Roux, 75724 Paris, France, on May 11, 2020, under the deposit numbers CNCM 1-5510 and CNCM 1-5511, respectively; and

a severe acute respiratory syndrome-associated coronavirus 2 spike protein (SARS-CoV-2 S protein).

2. A method for detection of a severe acute respiratory syndrome (SARS)-associated coronavirus infection in a biological sample comprising:

providing a biological sample;

contacting the biological sample with the SARS-CoV-2 N and SARS-CoV-2 S proteins of the kit of claim 1 ; and

detecting antigen-antibody complexes formed between antibodies in the biological sample and the SARS-CoV-2 N and SARS-CoV-2 S proteins.

3. The method of claim 2 , wherein the antibodies in the biological sample are immunoglobulin G (IgG).

4. The method of claim 2 , wherein the antibodies in the biological sample are immunoglobulin M (IgM).

5. The method of claim 2 , wherein the antibodies in the biological sample are immunoglobulin A (IgA).

6. The method of claim 2 , wherein the antibodies in the biological sample are IgG, IgM and IgA.

7. The method of claim 2 , wherein detecting antigen-antibody complexes comprises an enzyme-linked immunoassay.

8. The method of claim 2 , wherein detecting antigen-antibody complexes comprises a lateral flow immunoassay.

9. The method of claim 2 , wherein detecting antigen-antibody complexes comprises a bead-based immunoassay.

10. The method of claim 2 , wherein detecting antigen-antibody complexes comprises a multiplex bead-based immunoassay.

11. The method of claim 2 , wherein the SARS-CoV-2 N protein comprises SEQ ID NO:1.

12. The method of claim 2 , wherein the SARS-CoV-2 N protein consists of SEQ ID NO: 1.

13. The method of claim 2 , wherein the biological sample is obtained from an individual suspected to be infected with a SARS-associated coronavirus.

14. The method of claim 2 , wherein the biological sample is obtained from an individual infected with a SARS-associated coronavirus.

15. The method of claim 2 , wherein the biological sample is obtained from an individual infected with a SARS-CoV-2.

16. The method of claim 2 , wherein the biological sample is mixed with a visualizing monoclonal antibody prior to its being brought into contact with a capture antibody.

17. The method of claim 2 , wherein the antigen-antibody complexes are detected with an antibody or an antibody fragment that binds to human immunoglobulins.

18. The method of claim 17 , wherein the antibody or an antibody fragment that binds to human immunoglobulins is enzymatically labeled.

Assignments (2)

Continuity (2)

References Cited (15)